Rationale: Ischemic cardiovascular disease represents one of the largest epidemics currently facing the aging population. Current literature has illustrated the efficacy of autologous, stem cell therapies as novel strategies for treating these disorders. The CD34؉ hematopoetic stem cell has shown significant promise in addressing myocardial ischemia by promoting angiogenesis that helps preserve the functionality of ischemic myocardium. Unfortunately, both viability and angiogenic quality of autologous CD34؉ cells decline with advanced age and diminished cardiovascular health.
C ell-based therapies are rapidly emerging as a predominant new strategy for the treatment of various cardiovascular diseases that often involve acute or chronic ischemia. Preclinical and clinical studies have illustrated the beneficial effects of using human bone marrowderived CD34ϩ stem cells to treat conditions involving
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myocardial ischemia including refractory angina 1,2 and acute myocardial infarction (AMI). 3 A major benefit of using CD34ϩ stem cells in human patients is that the cell source is autologous, a unique characteristic that eliminates many of the inflammatory and toxicity concerns associated with nonautologous cells and/or pharmacological therapies. Although the exact nature of their therapeutic mechanism(s) is not entirely understood, it is believed that CD34ϩ stem cells promote the expansion of preexisting microvasculature (angiogenesis) and/or stimulate the de novo development of vascular structures (vasculogenesis) in ischemic regions of the cardiac muscle. 4 Recent evidence has identified a therapeutic paracrine mechanism of CD34ϩ cells as mediated in part by the secretion of extracellular, membrane-bound nanovesicles known as exosomes 5 that often carry proteins, RNAs, and/or microRNAs. 6 Nonetheless, the use of CD34ϩ cells as a strategy to enhance perfusion is known to preserve and/or improve cardiac function, [7] [8] [9] which may extend and improve the quality of life for the patient.
Although CD34ϩ cell-based therapies exhibit strong efficacy and safety profiles, the general cardiovascular health of a patient predicts both the relative availability and the therapeutic activity of the isolated cells. Health factors including smoking and alcohol abuse negatively impact circulating CD34ϩ cell levels. 10, 11 Additionally, circulating levels of CD34ϩ cells serve as indicators of cardiovascular outcome since densities of CD34ϩ cells in the circulation are commonly inversely proportional to both age and the severity of disease, [12] [13] [14] [15] indicating a natural time-dependent decrease in the angiogenic potential of CD34ϩ mobilized cells. These findings suggest that as cardiovascular disease worsens, autologous CD34ϩ cells become less capable of providing the intended therapeutic benefit. To counteract this cellular functional decline, several attempts have been made to boost the potency of autologous cells by using combinational therapies that codeliver known angiogenic genes and/or proteins along with stem cells. 16 -19 Despite these efforts, gene therapy remains a largely inefficient procedure requiring large doses of DNA in order to establish measurable target gene translation that has resulted in some phase II and phase III gene therapy trials failing to show gene-mediated therapeutic benefit. 20, 21 To improve delivery of the target gene while limiting the potential for adverse effects associated with off-target responses/poor gene transfer efficiency, we attempted to enhance the angiogenic quality of CD34ϩ cells by genetically modifying them to express the sonic hedgehog (Shh) protein.
Shh is a well-established angiogenic morphogen 22 and is known to play important roles in cardiac development 23 and postnatal ischemic injury recovery. 24 -26 Specifically, AMI is a known stimulus for the induction of Shh and its signaling components including the g-protein-coupled receptor patched1 and the downstream Gli transcription factors. 25 Importantly, postnatal induction of the Shh pathway has been shown to be protective against the tissue damage and cell death associated with ischemia because blockade of this pathway worsens outcome after experimental ischemia in rodents. 24 Accordingly, this study tested the hypothesis that Shhmodified human CD34ϩ cells provide enhanced functional benefit in the setting of AMI and that direct cellular modification provides a means to counteract age and disease related declines in the therapeutic potency of autologous cell therapy. Furthermore, these experiments also evaluated whether exosomes derived from Shh-modified CD34ϩ cells take part in this process.
Methods
Detailed Methods are provided in the Online Data Supplement.
Animal Models
Mice used in this study were obtained from The Jackson Laboratories (Bar Harbor, ME), and surgical procedures and animal care protocols were approved by the Northwestern University Animal Care and Use Committee. AMI injuries were induced (described previously 27 ) in 8-week-old male nude/J or NOD-SCID mice. Human CD34 ϩ cells were delivered as 2 to 10 L injections (on either side of the ligation) and contained either (1) 
Results

Expression of Shh in Modified CD34؉ Cells
After gene modification, both Shh mRNA and protein expression levels were assessed using quantitative polymerase chain reaction and ELISA, respectively. As compared with both CD34 NM and CD34 EV cells, CD34 Shh cells exhibited substantially higher levels of Shh mRNA ( Figure  1A ). Importantly, mRNA levels of Shh ( Figure 1A ) compared between CD34
EV and CD34 NM cells were not different indicating that modification alone failed to influence Shh expression. In terms of Shh protein ( Figure 1B) , both intracellular and extracellular (secreted) compartments of CD34 Shh cells expressed significantly higher levels of Shh when compared with CD34 EV cells. These results indicate that gene modification of CD34ϩ cells with the AMAXA system is effective and resulted in enhanced cellular Shh protein translation and secretion.
Additionally, fluorescence-activated cell sorting analysis with a panel of hematopoetic stem and non-stem cell surface antigens was used to evaluate whether gene modification or the presence of excess Shh acutely affected the CD34ϩ stem cell antigen profile. Analysis of the antigens CD34, CD45, CD38, CD41, Lin, CD133, and CD117 failed to reveal differences in antigen expression between CD34 NM , CD34 EV , and CD34
Shh at 24 hours after modification, indicating that neither modification or excess Shh acutely affects the antigenic identity of the cells (Online Figure I ).
CD34
Shh Significantly Enhances Preservation of Cardiac Function After AMI After gene modification, cells were injected into the ischemic border zone of immune-compromised mice to assess whether modification with Shh could provide superior functional preservation and/or improvement. To provide the largest possible window for detection of potential functional differ- Figure II, A) . Additionally, ejection fraction (EF), fractional shortening (FS), and left ventricular endsystolic and diastolic volumes were not different when compared between saline-treated, CD34
NM -treated, and CD34 EV -treated mice at 4 weeks after MI (Online Figure  II, A) . Conversely, doubling the cell dose to 5.0ϫ10 4 
NM cells did provide functional benefit over saline, indicating (1) the CD34ϩ cells used did possess therapeutic activity (Online Figure II, A) , and (2) the functional response was dose-dependent.
Interestingly, mice treated with 2.5ϫ10 4 CD34 Shh exhibited robust improvements in both EF and FS and also displayed decreased systolic and diastolic ventricular dilation as compared with all control mice (Figure 2A through 2E) . Significantly improved cardiac function induced by CD34 Shh was detected as early as 1 week after AMI and persisted to post-AMI weeks 2 and 4. These findings suggest that modification with Shh improves the therapeutic potency of CD34ϩ cells over CD34 NM .
CD34 Shh Reduce Infarct Size and Increase Border Zone Capillary Density
After euthanasia and tissue harvest at the 4-week time point, hearts from CD34 Shh -treated mice exhibited significantly reduced infarct dimensions as compared with all other treatments ( Figure 3A and 3B) . Additionally, using immunofluorescent detection of BS-1 lectin staining, capillary density was assessed within the infarct border zone of all hearts. Density of capillaries within the infarct border zone was significantly increased in hearts of mice treated with CD34
Shh as compared with control groups ( Figure 3C and 3D). Additionally, infarct size and capillary density (compared between CD34 NM -and CD34 EV -treated mice) were not different (Online Figure II , B and C), further validating the nontherapeutic nature of the subthreshold dose of CD34 NM .
CD34 Shh Exhibit Enhanced Postinjection Myocardial Retention
To address how the delivery of Shh via CD34
Shh influences cardiac function, we sought to determine if modification affects the intramyocardial retention of cells after direct cardiac injection. To evaluate this parameter, a subthreshold dose of either CD34
Shh or CD34 EV was injected into the ischemic border zone of hearts of NOD-SCID mice after AMI. At 1 and 5 days after cell administration, hearts were harvested, enzymatically digested and then stained with antibodies to HLA-ABC to quantify the viable human cells remaining in the mouse heart at each time point. As seen in Figure 4 , modification of CD34ϩ cells with Shh significantly improved the retention of live human cells in the myocardium at 24 hours after injection. In contrast, no difference between cell types was observed at 5 days after injection, perhaps reflecting a time-dependent loss of HLA antigenicity or continued clearance of cells.
Cotherapy of CD34 NM With Shh Protein Does Not Improve Cardiac Function
To understand the mechanisms behind the functional benefits observed with CD34 Shh , we explored whether canonical Shh pathway genes are induced in CD34ϩ cells after treatment with Shh protein or genetic modification. As seen in Figure  5A , treatment of CD34 NM with recombinant Shh (100 ng/mL) for 24 hours failed to stimulate the upregulation of mRNAs of Shh pathway components. Additionally, modification also failed to induce expression changes in Shh pathway components ( Figure 5B ). Last, several growth factors implicated in the paracrine, angiogenic activity of stem cells were also not regulated after Shh modification (data not shown), suggesting that activation of the canonical Shh signaling pathway in CD34ϩ cells is unlikely to be involved in the therapeutic benefit observed with CD34 Shh . To further explore the mechanism behind CD34 Shh mediated functional preservation, we assessed whether cotherapy of the subtherapeutic dose of CD34 NM along with recombinant Shh protein (200 ng/mouse) could replicate the functional benefits observed with CD34 Shh . As seen in Figure 5 , Shh protein coadministration along with CD34 NM produced no improvements in FS or EF ( Figure 5C and 5D) and also failed improve infarct size ( Figure 5E ) or border zone capillary density ( Figure 5F ). These findings may indicate that the functional preservation seen with CD34 Shh reflects the therapeutic necessity of a short-term, sustained secretion of Shh or the existence of a cellular Shh delivery process that is insufficiently replicated by the administration of a single injection of Shh protein.
CD34
Shh Specifically Package Overexpressed Shh in Secreted Exosomes
Exosomes derived from CD34 NM were recently characterized and have been shown to mediate a significant component of the angiogenic capacity of these cells. 5 To assess the nature by which Shh was being secreted by CD34 Shh , established exosomal purification methodologies 28 were used to determine whether the exosomal fraction of CD34 Shh conditioned media was involved. After purification ( Figure 6A ), it was determined that a significant fraction of the Shh protein secreted from CD34
Shh was found to be associated with small, membrane-enclosed vesicles known as exosomes (Figure 6B NM with recombinant Shh (50 ng/mL) failed to result in exosomal deposition of the protein, indicating that genetic modification of CD34ϩ cells is required to exploit any potential therapeutic benefit of exosome-mediated Shh delivery.
To determine whether Shh-containing exosomes derived from CD34
Shh could be mediating the observed functional benefits seen in the in vivo AMI model, we assessed whether exosomes derived from modified CD34ϩ cells could interact with another cell type. HUVECs were chosen as the recipient cell in this experiment for 2 specific reasons, including (1) the well-established importance of endothelial cell signaling and function in Shh-mediated angiogenesis and (2) the need for a recipient cell that fails standard pharmacological therapies. Perhaps the principal challenge to their adoption as standard therapy relates to the current inability to normalize their inherent reparative abilities across all patients, since individuals and their comorbidities vary immensely. Patient diversity in disease burden, age, and environmental factors alters the availability and therapeutic efficacy of isolated CD34ϩ cells. 10 -15 Given this serious and complex problem, we determined whether the therapeutic efficacy of CD34ϩ cells could be improved on by modifying them to express an established angiogenic protein, sonic hedgehog, to circumvent age and health related declines in CD34ϩ cell function. The use of the AMI model for these studies was directed by our previous success using autologous CD34ϩ cells for the treatment of refractory angina in human patients. 1 As presented in this report, CD34 Shh were observed to improve functional preservation of cardiac tissue as compared with control cells. Modification with Shh enhanced the therapeutic potency beyond that observed with a subtherapeutic dose (ie, 2.5ϫ10 4 cells) of CD34 NM , indicating that CD34 Shh could theoretically be used at lower doses than would be possible in their conventional form. This finding is significant given the problems associated with utilizing cell based therapies in poorly mobilizing patient populations such as those with ischemic 12, 29 or diabetic 30, 31 conditions. The finding that treatment with CD34 Shh induces robust increases in capillary development within the infarct border zone, accompanied by reduced infarct sizes, indicates that Shh-mediated angiogenesis is the likely mechanism for the observed functional improvements, although Shh-mediated transdifferentiation of resident fibroblasts to endothelial cells may also play a role. Given the abundance of information regarding the involvement of Shh-mediated repair of ischemic tissues, 24, 25, 32, 33 it is not surprising that cardiac function was preserved in mice treated with CD34 Shh . However, these findings do provide a number of novel insights, including (1) short-term secretion of Shh appears to be required for functional benefits to occur, (2) modification with Shh improves the short-term retention of CD34ϩ cells, (3) CD34 Shh deposit a proportionately greater amount of Shh in exosomes as compared with other Shh-modified cell types, (4) Shh-containing exosomes derived from CD34 Shh are capable of transferring Shh to other cell types, and (5) exosomes containing Shh activate Shh signaling pathways in other cell types.
The observation that functional improvement requires sustained Shh secretion is derived from the finding that coadministration of a single dose of Shh protein along with CD34 NM failed to replicate the in vivo functional benefits seen with CD34
Shh . These results suggest that although the injected cells appear to be of low abundance in the ischemic myocardium, their presence for at least 5 days after injection allows for the sustained secretion of Shh, thus greatly enhancing the propensity for Shh-mediated angiogenic signaling. Recombinant Shh has a serum half-life of approximately 1 hour although chemical modification of these proteins can improve the half-life upwards to 12 hours with equal or greater potency. 34 It remains to be determined whether (1) This argument is strengthened when considering that CD34 Shh were retained within the heart after local injection to a greater extent than control cells. Although improved retention of CD34 Shh cells was not resolved at day 5, a number of factors may be influencing the detection of retained cells at this time point, including (1) a loss of HLA-ABC antigenicity, (2) the general clearance of the cells over the 5-day time period, or (3) cell death. Given the difficulties of using immunohistochemical methods to quantify viable exogenous cells within cardiac tissue, we thought that enzymatic digestion of the whole heart followed by FACS analysis was a comprehensive method to quantify retention. Unfortunately, enzymatic digestion of the heart would be independently expected to cause cell death as well as potential antigen loss, suggesting that our results probably reflect an underestimate of the actual number of CD34ϩ cells retained in both conditions and at both time points. Further supporting the claim that sustained secretion of paracrine factors is required for the observed functional benefits of CD34 Shh cells, is an elegant report that utilized programmed apoptosis of endothelial progenitor cells (EPCs) after cardiac injection to show that the presence of EPCs weeks after injection continues to contribute to the sustained improvements in cardiac function attributable to EPC function. 35 One could also speculate that Shh-modification of CD34ϩ cells may affect adherence of cells within cardiac tissue by regulating expression of adhesion proteins and could be addressed in future experiments via cellular protein profiling. Another potential avenue of examination includes determining whether local Shh signaling processes alter the cell surface landscape of resident cardiac cells to assist in retaining therapeutic exogenous cells within that specific location.
Along these lines, attempts to determine whether Shh treatment (ie, protein treatment or Shh-modification) acutely influenced CD34ϩ cells revealed no induction of endogenous Shh pathway components ( Figure 5A and 5B) or the differentiation capacity of CD34ϩ cells (Online Figure I) . Analysis at later time points for both assays may reveal more obvious long term effects not seen at the time points assessed in this study. With the recent characterization of a noncanonical Shh signaling pathway in endothelial cells, 36, 37 it is conceivable that the direct action of Shh on CD34ϩ cells may also utilize this pathway. Nonetheless, delivery of CD34 Shh within 24 hours of modification was clearly sufficient to provide therapeutic benefit in vivo.
Together, these results indicate that CD34 Shh acted primarily as a secretory vehicle to deliver Shh to the ischemic tissue they were injected into. Although an autocrine effect of Shh on CD34
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Shh was not observed (as has been seen in Shhmodified mesenchymal stem cells 38 ), both modified stem cell types provide significant protection against functional deficits associated with AMI. Given our laboratory's recent discovery that CD34ϩ cells actively secrete exosomes as a major component of their paracrine-mediated reparative abilities, 5 we explored whether the overexpression of Shh in modified CD34
Shh would allow us to determine (1) whether CD34 Shh selectively package Shh into exosomes and (2) whether this mechanism had any functional implications for Shh signaling in other cell types. Fortunately, the gene modification approach allowed for the elucidation of exosomal mechanisms that, to this point, have been difficult to observe owing to their extremely small cargo load. We determined that CD34
Shh divert approximately Ϸ25% of their secreted Shh into exosomes and that this process appears to be cell type-selective, given that other Shh-modified cell types such as HUVECs and HeLa cells secrete Shh almost exclusively as free protein. The observed exosomal deposition of Shh in CD34 Shh does not appear to result from excess protein load, given that the absolute amount of protein secreted by the other cell types was generally higher. It should also be mentioned that exposing CD34 NM to Shh protein did not result in its exosomal deposition, which reinforces the notion that CD34ϩ cells must be genetically modified in order to exploit therapeutic exosomal mechanisms.
Despite our knowledge that stem cell and cancer cellderived exosomes possess angiogenic abilities independent of the cell type they are derived from, 5,39 -42 the mechanistic basis of their action is still under investigation. Our finding that exosomes derived from CD34 Shh physically transfer Shh to other cell types adds to this knowledge. Although emerging evidence is suggesting that exosomes also harbor mRNA and/or miRNAs that can be transferred to other cell types where they mediate expression changes in target cells, 43, 44 to our knowledge, no report currently exists that depicts the ability of CD34ϩ cell-derived exosomes to transfer functional protein. Presumably, failure to observe exosomalmediated protein transfer is derived from the difficulty associated with detecting low abundance proteins; however, the genetic modification procedure utilized here has allowed for the observation of this process. Although the possibility exists that Shh-containing exosomes were simply adhering to HUVECs, our methodology, which included multiple vigorous cell washes followed by centrifugation, indicates that any outer cell membrane adherence that did occur was apparently a physiologically relevant association.
Our observation that exosomal Shh also activated the Shh signaling pathway in fibroblasts, evidenced by upregulation of Gli-luciferase activity in NIH3T3 fibroblasts, supports the belief that exosomes promote meaningful communication between cells. Although the luciferase response induced by CD34 Shh exosomes was modest as compared with free recombinant protein (see Online Figure III, B) , the absolute level of the response was actually very robust when compared with the amount of Shh protein actually found in CD34 Shh exosomes (see Online Figure III, A) . This finding suggests that exosome-mediated activation of cell signaling may actually be more efficient than that caused by free protein.
Because exosomes are membrane bound vesicles, they would be expected to protect their cargo from destructive extracellular proteases and thereby enhance cell signaling events. From a clinical standpoint, the delivery of exosomes may offer several advantages over cell delivery, a few of which include (1) the ability to deliver a treatment that may possess a higher therapeutic potency than modified cells, (2) the avoidance of triggering potentially damaging cell clearance mechanisms after injection, and (3) potential "expansion" of therapeutic exosomes via short-term culturing of isolated CD34ϩ cells. Current work in the laboratory is focused on further investigation of the mechanistic basis by which CD34ϩ cell-derived exosomes generate in vivo angiogenic responses in hind limb and myocardial ischemia models. As our knowledge regarding these interesting cellular components expands, it is likely that the true nature of their activity will resemble a combination of multiple mechanisms that will be regulated both contextually and temporally. 
Novelty and Significance
What Is Known?
• CD34ϩ cells are known to stimulate therapeutic neovascularization in preclinical studies as well as in phase I and II human clinical trials, and the potency of CD34ϩ cells is greater than for unselected mononuclear cells.
• Sonic hedgehog (Shh) is a well-established angiogenic morphogen capable of stimulating postnatal angiogenesis after an acute ischemic insult.
• Both the number of CD34ϩ cells and their inherent angiogenic functionality are diminished in patients of increasing age and cardiovascular disease burden.
• Exosomes are small, membrane-bound vesicles secreted from many cell types that harbor protein and nucleic acids and have been implicated in cell-to-cell signaling mechanisms.
What New Information Does This Article Contribute?
• Genetic modification of CD34ϩ cells with Shh imparts therapeutic efficacy to a previously determined subtherapeutic dose of nonmodified CD34ϩ cells after myocardial infarction. ng/ml vascular endothelial growth factor, 50 ng/ml Flt-3 ligand, 20 ng/ml stem cell factor and 10 ng/ml thrombopoetin (PeproTech, Rocky Hill, NJ) and 0.25% human serum albumin (Baxter Healthcare, Deerfield, IL) at a density of one million cells/ml of media.
All experiments involving CD34+ cells including exosome production and mRNA analysis were conducted in the complete media described above. Harvest of Cardiac Tissue, Histology and Immunofluorescent Assesments: All hearts were harvested after the 28 day echocardiographic analysis as described previously. 4, 5 To prepare paraffin-embedded sections, the abdominal aorta was cannulated with a polyethylene catheter containing phosphate buffered saline (PBS, 0.2 M, pH 7.4).
Immediately after the cannulation, 1 mL of PBS/heparin solution was injected, and the heart was arrested in the diastolic phase by injecting 0.15 mL of 100 mM cadmium chloride through the catheter. The thorax was then opened and the heart was perfused at mean arterial pressure with methanol, and the right atrium was cut to allow drainage. Exosome Purification: Exosomes were isolated from CD34+, HUVEC and HeLa cells using a previously published ultracentrifugation protocol. 6 Briefly, cells were pelleted by centrifugation at 400g for 15 minutes at which point the supernatant containing the exosomes was transferred to an ultracentrifuge tube. Samples were then centrifuged at 14,000g (~14000rpm) for 30 min at 4° using a Beckman ultracentrifuge equipped with a
Type 70 Ti rotor. The supernatant was then extracted and layered on top of 4 ml of 30% sucrose/D 2 O (pH = 7.4) and centrifuged at 100,000g (37,000 rpm) for 60 min at 4°.
The top layer, including the blurry interface, was then aspirated. The remaining supernatant (approximately 3.5 ml) was then transferred to a new tube and resuspended in 20 ml of PBS and centrifuged once more at 100,000g for 60 min at 4°.
The remaining supernatant was then aspirated leaving only the exosomal pellet. The pellet was then re-suspended in media according to which experiment was to be performed.
Electron Microscopy: Exosomes from CD34 Shh cells were stained for electron microscopy following published methods. 6 Briefly, the isolated exosomes were fixed and frozen at -80°C. Luciferase activity was assayed with a Luciferase assay system (Promega) and β-galactosidase activity was assayed as previously described. 7 . For each sample, luciferase activity was normalized to β-galactosidase activity to compensate for differences in transfection efficiency. Each condition was assayed in triplicate, and each experiment was performed at least two times. The Gli-BS luciferase plasmid was kindly provided by Dr H. Sasaki. 
